Identification of a RAD52 Inhibitor Inducing Synthetic Lethality in BRCA2-Deficient Cancer Cells

The breast cancer susceptibility gene 1/2 (BRCA1/2) is frequently mutated in many malignant tumors, such as breast cancer and ovarian cancer. Studies have demonstrated that inhibition of RAD52 gene function in BRCA2-deficient cancer causes synthetic lethality, suggesting a potential application of R...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Qianye, Li, Yu, Sun, Rong, Li, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8118686/
https://www.ncbi.nlm.nih.gov/pubmed/33995041
http://dx.doi.org/10.3389/fphar.2021.637825

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8118686/
https://www.ncbi.nlm.nih.gov/pubmed/33995041
http://dx.doi.org/10.3389/fphar.2021.637825

Ejemplares similares